Jiang X L, Gu T Y, Liu L, Song J, Zhou X Y, Guo Z
Deartment of Anesthesiology, the 2nd Affiliated Hosital of Nantong University, Nantong 226001, China.
Deartment of Extracororeal Circulation, Shanghai Chest Hospital, Shanghai 200030, China.
Zhonghua Yi Xue Za Zhi. 2019 Dec 24;99(48):3770-3774. doi: 10.3760/cma.j.issn.0376-2491.2019.48.003.
To investigate the safety and myocardial protective effect of del Nido cardioplegia in coronary artery bypass grafting combined with heart valve replacement in adults. From April 2018 to April 2019, 84 patients undergoing coronary artery bypass grafting combined with heart valve replacement under cardiopulmonary bypass (CPB) in the Second Affiliated Hospital of Nantong University and Shanghai Chest Hospital were selected, and divided into del Nido cardioplegia (44) group and Thomas cardioplegia (40) group using a random number table. The concentration of troponin was measured before anesthesia induction and 2, 12 and 24 hours after the termination of CPB, respectively. The preoperative characteristics of each group were similar, including age, underlying diseases, and body surface area (all 0.05). The frequency of intraoperative cardioplegia infusion in the del Nido group was significantly lower than that in the Thomas group (0.03). Compared with the del Nido group, troponin concentration in the Thomas group increased significantly at 12 hours [(4.59±0.76) μg/L vs (2.20±0.53) μg/L, -16.653, 0.001] and 24 hours [(6.70±0.97) μg/L vs (1.96±0.58) μg/L, -26.975, 0.001] after CPB. No statistically significant differences were found in the postoperative recovery of cardiac autonomic rhythm (0.887), cardiac defibrillation (0.880), positive inotropic drugs (0.163) and left ventricular ejection fraction (0.338) between the two groups. It is safe to use del Nido cardioplegia in coronary artery bypass grafting combined with heart valve replacement in adults, which can reduce the frequency of cardioplegia infusion and simplify the surgical procedure. The trend of troponin concentration suggests that del Nido cardioplegia has a better myocardial protective effect.
探讨成人冠状动脉旁路移植术联合心脏瓣膜置换术中应用德尔尼多停搏液的安全性及心肌保护效果。选取2018年4月至2019年4月在南通大学第二附属医院和上海胸科医院行体外循环(CPB)下冠状动脉旁路移植术联合心脏瓣膜置换术的84例患者,采用随机数字表法分为德尔尼多停搏液组(44例)和托马斯停搏液组(40例)。分别于麻醉诱导前、CPB结束后2、12和24小时测定肌钙蛋白浓度。两组术前特征相似,包括年龄、基础疾病和体表面积(均P>0.05)。德尔尼多组术中停搏液输注频率显著低于托马斯组(P<0.03)。与德尔尼多组相比,托马斯组CPB后12小时[(4.59±0.76)μg/L比(2.20±0.53)μg/L,t=-16.653,P=0.001]和24小时[(6.70±0.97)μg/L比(1.96±0.58)μg/L,t=-26.975,P=0.001]肌钙蛋白浓度显著升高。两组术后心脏自主节律恢复情况(P=0.887)、心脏除颤情况(P=0.880)、正性肌力药物使用情况(P=0.163)及左心室射血分数(P=0.338)比较,差异均无统计学意义。成人冠状动脉旁路移植术联合心脏瓣膜置换术中应用德尔尼多停搏液是安全的,可减少停搏液输注频率,简化手术操作。肌钙蛋白浓度变化趋势提示德尔尼多停搏液具有更好的心肌保护作用。